Edith D van der Meijden
Overview
Explore the profile of Edith D van der Meijden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
305
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kremer A, Kremer A, Willam C, Volkl S, Verhagen J, Achenbach S, et al.
Eur J Immunol
. 2021 Aug;
51(10):2478-2484.
PMID: 34350584
Treatment with convalescent plasma has been shown to be safe in coronavirus disease in 2019 (COVID-19) infection, although efficacy reported in immunocompetent patients varies. Nevertheless, neutralizing antibodies are a key...
2.
Bernhardt A, Zeun J, Marecek M, Reimann H, Kretschmann S, Bausenwein J, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34266882
Background: Graft-versus-host-disease (GvHD) is a major problem in allogeneic stem cell transplantation. We previously described two types of endogenous human leukocyte antigen (HLA)-II restricted antigens depending on their behavior towards...
3.
Reimann H, Nguyen A, Sanborn J, Vaske C, Benz S, Niazi K, et al.
J Immunother Cancer
. 2021 Jun;
9(6).
PMID: 34172517
Background: Therapeutic regimens designed to augment the immunological response of a patient with breast cancer (BC) to tumor tissue are critically informed by tumor mutational burden and the antigenicity of...
4.
Verhagen J, van der Meijden E, Lang V, Kremer A, Volkl S, Mackensen A, et al.
Clin Exp Immunol
. 2021 Jun;
205(3):363-378.
PMID: 34061349
Since December 2019, Coronavirus disease-19 (COVID-19) has spread rapidly throughout the world, leading to a global effort to develop vaccines and treatments. Despite extensive progress, there remains a need for...
5.
Fuchs K, Honders M, van der Meijden E, Adriaans A, van der Lee D, Pont M, et al.
Front Immunol
. 2020 May;
11:659.
PMID: 32362897
Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated...
6.
Arindrarto W, Borras D, de Groen R, van den Berg R, Locher I, van Diessen S, et al.
Leukemia
. 2020 Mar;
35(1):47-61.
PMID: 32127641
Acute myeloid leukemia (AML) is caused by genetic aberrations that also govern the prognosis of patients and guide risk-adapted and targeted therapy. Genetic aberrations in AML are structurally diverse and...
7.
Kretschmann S, Herda S, Bruns H, Russ J, van der Meijden E, Schlotzer-Schrehardt U, et al.
J Clin Invest
. 2019 Jun;
129(7):2952-2963.
PMID: 31205025
Recent studies have demonstrated that CD4+ T cells can efficiently reject MHC-II-negative tumors. This requires indirect presentation of tumor-associated antigens on surrounding antigen-presenting cells. We hypothesized that intercellular transfer of...
8.
Pont M, Oostvogels R, van Bergen C, van der Meijden E, Honders M, Bliss S, et al.
Cancer Immunol Res
. 2019 Mar;
7(5):797-804.
PMID: 30890530
MHC-bound peptides from aberrant proteins may be a specific immunotherapeutic target on cancer cells. Because of difficulties in identifying such antigens, viral or model antigens have so far been used...
9.
Kremer A, Zonneveld M, Kremer A, van der Meijden E, Falkenburg J, Wauben M, et al.
Eur J Immunol
. 2018 Jul;
48(10):1621-1631.
PMID: 30011060
CD4 T cells play a central role as helper cells in adaptive immunity. Presentation of exogenous antigens in MHC class II by professional antigen-presenting cells is a crucial step in...
10.
Pont M, van der Lee D, van der Meijden E, van Bergen C, Kester M, Honders M, et al.
Clin Cancer Res
. 2016 Mar;
22(16):4185-96.
PMID: 26964570
Purpose: In HLA-matched allogeneic hematopoietic stem cell transplantation (alloSCT), donor T cells recognizing minor histocompatibility antigens (MiHAs) can mediate desired antitumor immunity as well as undesired side effects. MiHAs with...